Want to join the conversation?
$MDT is seeing strong acceptance for its new therapies across all groups. Including the benefit of extra week, emerging markets growth vector contributed approx. 190BP to 1Q16 total growth. Regionally, Middle East and Africa was weaker, but $MDT reported notable improvements China (low double digits), India (mid teens), and Russia (upper teens).
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.